Literature DB >> 29472354

Efficacy and safety of high-dose etoposide cytarabine as consolidation following rituximab methotrexate temozolomide induction in newly diagnosed primary central nervous system lymphoma in immunocompetent patients.

Rudy Birsen1,2, Lise Willems1,2, Johan Pallud1,3, Estelle Blanc4, Barbara Burroni1,5, Marielle Legoff1,2, Emmanuelle Le Ray1,2, Sylvain Pilorge2, Benedicte Deau1,2, Patricia Franchi1,2, Marguerite Vignon1,2, Yioula Kirova6, Myriam Edjlali1,7, Caroline Houillier8, Carole Soussain9, Pascale Varlet10, Edouard Dezamis1,3, Diane Damotte1,5, Didier Bouscary1,2, Jerome Tamburini11,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29472354      PMCID： PMC6029551          DOI： 10.3324/haematol.2017.185843

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  15 in total

1.  R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma.

Authors:  Antonio Omuro; Denise D Correa; Lisa M DeAngelis; Craig H Moskowitz; Matthew J Matasar; Thomas J Kaley; Igor T Gavrilovic; Craig Nolan; Elena Pentsova; Christian C Grommes; Katherine S Panageas; Raymond E Baser; Geraldine Faivre; Lauren E Abrey; Craig S Sauter
Journal:  Blood       Date:  2015-01-07       Impact factor: 22.113

2.  High-dose chemotherapy with autologous haemopoietic stem cell transplantation for newly diagnosed primary CNS lymphoma: a prospective, single-arm, phase 2 trial.

Authors:  Gerald Illerhaus; Benjamin Kasenda; Gabriele Ihorst; Gerlinde Egerer; Monika Lamprecht; Ulrich Keller; Hans-Heinrich Wolf; Carsten Hirt; Stephan Stilgenbauer; Mascha Binder; Peter Hau; Matthias Edinger; Norbert Frickhofen; Martin Bentz; Robert Möhle; Alexander Röth; Michael Pfreundschuh; Louisa von Baumgarten; Martina Deckert; Claudia Hader; Heidi Fricker; Elke Valk; Elisabeth Schorb; Kristina Fritsch; Jürgen Finke
Journal:  Lancet Haematol       Date:  2016-07-13       Impact factor: 18.959

3.  Immunochemotherapy with intensive consolidation for primary CNS lymphoma: a pilot study and prognostic assessment by diffusion-weighted MRI.

Authors:  Matthew J Wieduwilt; Francisco Valles; Samar Issa; Caroline M Behler; James Hwang; Michael McDermott; Patrick Treseler; Joan O'Brien; Marc A Shuman; Soonmee Cha; Lloyd E Damon; James L Rubenstein
Journal:  Clin Cancer Res       Date:  2012-01-06       Impact factor: 12.531

4.  Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial.

Authors:  Andrés J M Ferreri; Kate Cwynarski; Elisa Pulczynski; Maurilio Ponzoni; Martina Deckert; Letterio S Politi; Valter Torri; Christopher P Fox; Paul La Rosée; Elisabeth Schorb; Achille Ambrosetti; Alexander Roth; Claire Hemmaway; Angela Ferrari; Kim M Linton; Roberta Rudà; Mascha Binder; Tobias Pukrop; Monica Balzarotti; Alberto Fabbri; Peter Johnson; Jette Sønderskov Gørløv; Georg Hess; Jens Panse; Francesco Pisani; Alessandra Tucci; Stephan Stilgenbauer; Bernd Hertenstein; Ulrich Keller; Stefan W Krause; Alessandro Levis; Hans J Schmoll; Franco Cavalli; Jürgen Finke; Michele Reni; Emanuele Zucca; Gerald Illerhaus
Journal:  Lancet Haematol       Date:  2016-04-06       Impact factor: 18.959

5.  Phase I and II Study of Induction Chemotherapy With Methotrexate, Rituximab, and Temozolomide, Followed By Whole-Brain Radiotherapy and Postirradiation Temozolomide for Primary CNS Lymphoma: NRG Oncology RTOG 0227.

Authors:  Jon Glass; Minhee Won; Christopher J Schultz; Daniel Brat; Nancy L Bartlett; John H Suh; Maria Werner-Wasik; Barbara Jean Fisher; Marcia K Liepman; Mark Augspurger; Felix Bokstein; Joseph A Bovi; Matthew C Solhjem; Minesh P Mehta
Journal:  J Clin Oncol       Date:  2016-03-28       Impact factor: 44.544

6.  Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202).

Authors:  James L Rubenstein; Eric D Hsi; Jeffrey L Johnson; Sin-Ho Jung; Megan O Nakashima; Barbara Grant; Bruce D Cheson; Lawrence D Kaplan
Journal:  J Clin Oncol       Date:  2013-04-08       Impact factor: 44.544

7.  Phase 2 trial of high-dose rituximab with high-dose cytarabine mobilization therapy and high-dose thiotepa, busulfan, and cyclophosphamide autologous stem cell transplantation in patients with central nervous system involvement by non-Hodgkin lymphoma.

Authors:  Yi-Bin Chen; Tracy Batchelor; Shuli Li; Ephraim Hochberg; Mark Brezina; Sooae Jones; Candice Del Rio; Morgan Curtis; Karen K Ballen; Jeffrey Barnes; Andrew S Chi; Jorg Dietrich; Jessica Driscoll; Elizabeth R Gertsner; Fred Hochberg; Ann S LaCasce; Steven L McAfee; Thomas R Spitzer; Lakshmi Nayak; Philippe Armand
Journal:  Cancer       Date:  2014-09-09       Impact factor: 6.860

8.  Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial.

Authors:  Andrés J M Ferreri; Kate Cwynarski; Elisa Pulczynski; Christopher P Fox; Elisabeth Schorb; Paul La Rosée; Mascha Binder; Alberto Fabbri; Valter Torri; Eleonora Minacapelli; Monica Falautano; Fiorella Ilariucci; Achille Ambrosetti; Alexander Roth; Claire Hemmaway; Peter Johnson; Kim M Linton; Tobias Pukrop; Jette Sønderskov Gørløv; Monica Balzarotti; Georg Hess; Ulrich Keller; Stephan Stilgenbauer; Jens Panse; Alessandra Tucci; Lorella Orsucci; Francesco Pisani; Alessandro Levis; Stefan W Krause; Hans J Schmoll; Bernd Hertenstein; Mathias Rummel; Jeffery Smith; Michael Pfreundschuh; Giuseppina Cabras; Francesco Angrilli; Maurilio Ponzoni; Martina Deckert; Letterio S Politi; Jürgen Finke; Michele Reni; Franco Cavalli; Emanuele Zucca; Gerald Illerhaus
Journal:  Lancet Haematol       Date:  2017-10-17       Impact factor: 18.959

Review 9.  The role of autologous stem cell transplantation in primary central nervous system lymphoma.

Authors:  Andrés J M Ferreri; Gerald Illerhaus
Journal:  Blood       Date:  2016-02-01       Impact factor: 22.113

10.  High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study).

Authors:  K Fritsch; B Kasenda; E Schorb; P Hau; J Bloehdorn; R Möhle; S Löw; M Binder; J Atta; U Keller; H-H Wolf; S W Krause; G Heß; R Naumann; S Sasse; C Hirt; M Lamprecht; U Martens; A Morgner; J Panse; N Frickhofen; A Röth; C Hader; M Deckert; H Fricker; G Ihorst; J Finke; G Illerhaus
Journal:  Leukemia       Date:  2016-11-15       Impact factor: 11.528
View more
  4 in total

1.  Chemoradiotherapy with temozolomide after high-dose methotrexate for primary CNS lymphoma: a multicenter phase I study of a response-adapted strategy.

Authors:  Silvia Chiesa; Stefan Hohaus; Lorenzo Falcinelli; Francesco D'Alò; Massimo Fabrizio Martelli; Stefania Manfrida; Francesco Beghella Bartoli; Cesare Colosimo; Vincenzo Valentini; Cynthia Aristei; Mario Balducci
Journal:  Ann Hematol       Date:  2020-08-20       Impact factor: 3.673

2.  Outcomes Associated With Thiotepa-Based Conditioning in Patients With Primary Central Nervous System Lymphoma After Autologous Hematopoietic Cell Transplant.

Authors:  Michael Scordo; Trent P Wang; Kwang W Ahn; Yue Chen; Sairah Ahmed; Farrukh T Awan; Amer Beitinjaneh; Andy Chen; Victor A Chow; Bhagirathbhai Dholaria; Narendranath Epperla; Umar Farooq; Nilanjan Ghosh; Natalie Grover; Nada Hamad; Gerhard C Hildebrandt; Leona Holmberg; Sanghee Hong; David J Inwards; Antonio Jimenez-Jimenez; Reem Karmali; Vaishalee P Kenkre; Farhad Khimani; Evgeny Klyuchnikov; Maxwell M Krem; Pashna N Munshi; Yago Nieto; Tim Prestidge; Praveen Ramakrishnan Geethakumari; Andrew R Rezvani; Peter A Riedell; Sachiko Seo; Nirav N Shah; Melhem Solh; Jean A Yared; Mohamed A Kharfan-Dabaja; Alex Herrera; Mehdi Hamadani; Craig S Sauter
Journal:  JAMA Oncol       Date:  2021-07-01       Impact factor: 31.777

3.  High-dose Methotrexate plus temozolomide with or without rituximab in patients with untreated primary central nervous system lymphoma: A retrospective study from China.

Authors:  Cui Chen; Peng Sun; Juan Cui; Shumei Yan; Hao Chen; Yi Xia; Xiwen Bi; Panpan Liu; Yu Wang; Hang Yang; Man Nie; Xue-Wen Zhang; Wenqi Jiang; Zhi-Ming Li
Journal:  Cancer Med       Date:  2019-03-01       Impact factor: 4.452

4.  Efficacy and Safety of Autologous Stem-Cell Transplantation as Part of First-Line Treatment for Newly Diagnosed Primary Central Nervous System Lymphoma: A Systematic Review and Meta-Analysis.

Authors:  Jing Liu; Jiayuan Guo; Xuefei Sun; Yuanbo Liu; Chunji Gao
Journal:  Front Oncol       Date:  2022-01-12       Impact factor: 6.244
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.